Abstract: The present invention relates to novel compounds of general formula (I) and (II) for their use in gene therapy as non-viral vehicles and their use for the preparation of a medicament. It also discloses the process of synthesis of said compounds of general formula (I) and (II).

Abstract: The present invention relates to a type of peritoneal dialysis solution that comprises aliskiren or any of its derivatives, at least one electrolyte, at least one buffer solution and at least one osmotic agent. This enables toxicity reduction in these habitually used peritoneal dialysis solutions with respect to peritoneal mesothelial cells. On the other hand, the present invention relates to the use of these types of solutions in processes requiring peritoneal dialysis, as in the case of chronic renal failure.

Abstract: Use of a compound corresponding to formula (I) in which R represents hydrogen or a group chosen from alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene, cycloalkylidyne and —CONH2 groups, and the —COR? and —COOR? groups, in which R? is chosen from alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene and cycloalkylidyne groups, it being possible for said groups R and/or R? to be substituted and/or interrupted with -0-, —COO—, —OCO—, —NHCO— or —CONH— functions, or a pharmaceutically acceptable salt of said compound, for obtaining a medicament for use in the treatment of faecal incontinence.